LNC’s Latest Progress in Radiopharmaceuticals Innovative Research at the European Association of Nuclear Medicine Annual Congress 2023-Company News-Yantai Lannacheng Biotechnology Co., Ltd.

LNC’s Latest Progress in Radiopharmaceuticals Innovative Research at the European Association of Nuclear Medicine Annual Congress 2023

2023-09-19 10:14:58 556

Sept. 14, 2023, Vienna

Recently, at the European Association of Nuclear Medicine 36th Annual Congress (EANM2023, Sept. 9-13th, 2023), Vienna, Austria, LNC once again introduced its innovative research achievements in the field of radionuclide diagnosis and treatment, which obtained great attention and recognition from international peers. In this meeting, LNC shared its latest progress in nuclear medicine research with 9 speeches (including 3 Feature papers and 6 TOP papers) and 3 posters. EANM is the world's leading professional conference in the field of nuclear medicine, bringing together experts and scholars in nuclear medicine from all over the world to share and discuss the latest scientific research results. The trip was led by Prof. Chen Xiaoyuan, Co-founder and Chief Scientific Officer of LNC, and Prof. Zhang Jingjing, Chief Medical Officer of LNC and Professor of National University of Singapore, together with the company's core team and collaborators.

Main research highlights presented at this conference:

—— Research Highlights 01 ——

LNC is currently conducting clinical drug conversion studies in multiple centers worldwide for FAP-targeted radiotheranostic products with multiple IND approvals. Prof. Zhang Jingjing enthusiastically reported on the latest research progress of FAPI-targeted therapeutic products at the meeting. The latest progress of the first-in-human study of β and α-emitting therapeutic radionuclide 177Lu, 90Y, 225Ac-labeled novel FAP-targeted nuclide drugs in a variety of advanced solid tumors provides a strong technical reserve for the future development of FAPI therapeutics, and demonstrates LNC's foresight and sagacity in the development of innovative radionuclide therapeutic drugs.

—— Research Highlights 02 ——

Therapeutic study of 177Lu-LNC1003 in Metastatic Castration Resistant Prostate Cancer (mCRPC): Dr. Zang Jie from the First Affiliated Hospital of Fujian Medical University introduced the safety, dosimetry, and efficacy of 177Lu-LNC1003 in mCRPC. The first-in-human preliminary results showed that compared with 177Lu-EB-PSMA and 177Lu-PSMA-617, 177Lu-LNC1003 has higher uptake and accumulation in tumors, and was well tolerated at low dose administration. This study has recently been published in the European Journal of Nuclear Medicine and Molecular Imaging, a top journal in nuclear medicine.

—— Research Highlights 03 ——

First-in-human dosimetry study of 177Lu-LNC1004: Prof. Chen Haojun, the First Affiliated Hospital of Xiamen University, reported a study on the first-in-human dose escalation study of 177Lu-LNC1004 in patients with metastatic refractory thyroid cancer. The research results indicated that 177Lu-LNC1004 was well tolerated in all patients and demonstrated increased tumor uptake and prolonged residence time. At doses of 3.33-3.7GBq/cycle, 177Lu-LNC1004 showed acceptable side effects, high tumor enrichment, and good therapeutic efficacy. This study has also recently been published in the Clinical Cancer Research, the top- journal of cancer research.

—— Research Highlights 04 ——

Application of 68Ga-LNC1007 in malignant tumors: Dr. Pang Yizhen from the Department of Nuclear Medicine, First Affiliated Hospital of Xiamen University, reported the application of the FAP and integrin receptors-targeted 68Ga-LNC1007 (68Ga-FAPI-RGD) in different types of malignant tumors. Compared with 18F-FDG and 68Ga-FAPI PET/CT, 68Ga-LNC1007 demonstrated a better tumor uptake and tumor to background ratio, showing advantages in the diagnosis and staging of malignancies. This research has been published in the Journal of Nuclear Medicine and Theranostics, etc.

—— Research Highlights 05 ——

The efficacy of 68Ga-LNC1007 in the diagnosis of kidney cancer: Dr. Lin Rong, the First Affiliated Hospital of Fujian Medical University, reported the efficacy study of 68Ga-LNC1007 (68Ga-FAPI-RGD) in the diagnosis of kidney cancer and compared it with 18F-FDG/68Ga-PSMA PET/CT. The study involved 28 subjects, 25 of whom were pathologically confirmed to have kidney cancer. 68Ga-FAPI-RGD PET/CT has a significantly better detection rate for primary lesions than 18F-FDG and 68Ga-PSMA PET/CT. This study has recently been published in the European Journal of Nuclear Medicine and Molecular Imaging.

LNC has once again brought innovation and breakthroughs in the fields of nuclear medicine and oncology radiotheranostics with its cutting-edge research achievements. LNC will continue to strengthen its R&D capacity in nuclear medicine to bring more precise and effective diagnostic and treatment plans to patients.